CoChat

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Open access
Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L · 2018 · Nephrology Dialysis Transplantation

The DOI matches its Crossref record; 28 of the 47 references it cites were found in a registry or an index.

Abstract

Background: The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this drug have not been properly defined in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (CKD). Methods: In a pooled analysis of 11 phase 3 randomized controlled clinical trials, we determined least square mean changes in HbA1c, body weight, BP, estimated glomerular filtration rate (eGFR) and UACR over 102 weeks in patients with type 2 diabetes and an eGFR between 12 to less than 45 mL/min/1.73 m2 receiving placebo (n = 69) or dapagliflozin 5 or 10 mg (n = 151). Effects on UACR were determined in a subgroup of patients with baseline UACR ≥30 mg/g (n = 136). Results: Placebo-corrected changes in HbA1c with dapagliflozin 5 and 10 mg were 0.03% [95% confidence interval (CI) -0.3-0.3] and 0.03% (95% CI -0.2-0.3) during the overall 102-week period. Dapagliflozin 5 and 10 mg compared with placebo reduced UACR by - 47.1% (95% CI -64.8 to - 20.6) and -38.4% (95% CI -57.6 to - 10.3), respectively. Additionally, dapagliflozin 5 and 10 mg compared with placebo reduced BP and body weight. eGFR increased with placebo during the first 4 weeks but did not change with dapagliflozin. There were no between-group differences in eGFR at the end of follow-up. Adverse events associated with renal function occurred more frequently in the dapagliflozin 10-mg group. These events were mainly asymptomatic increases in serum creatinine. Conclusions: Dapagliflozin did not decrease HbA1c in patients with type 2 diabetes and Stages 3b-4 CKD, but decreased UACR, BP and body weight to a clinically meaningful extent. These results support a large outcome trial in this population to confirm long-term safety and efficacy in reducing adverse clinical endpoints.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfx350

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Changes in parameters of kidney function over time during treatment with placebo or dapagliflozin: (A) eGFR, (B) UACR, (C) phosphate, (D) potassium. *UACR analysis (UACR ≥30 mg/g): n = 42 for placebo, n = 37 for dapagliflozin 5 mg and n = 57 for dapagliflozin 10 mg. BL, baseline.
FIGURE 1 Changes in parameters of kidney function over time during treatment with placebo or dapagliflozin: (A) eGFR, (B) UACR, (C) phosphate, (D) potassium. *UACR analysis (UACR ≥30 mg/g): n = 42 for placebo, n = 37 for dapagliflozin 5 mg and n = 57 for dapagliflozin 10 mg. BL, baseline.CC BY-NC · PubMed Central
FIGURE 2 Changes in renal or cardiovascular risk markers over time during treatment with placebo or dapagliflozin: (A) hematocrit, (B) systolic blood pressure (SBP), (C) body weight, (D) uric acid.
FIGURE 2 Changes in renal or cardiovascular risk markers over time during treatment with placebo or dapagliflozin: (A) hematocrit, (B) systolic blood pressure (SBP), (C) body weight, (D) uric acid.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 102

Metadata

Authors
Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L.
Affiliations
  • University Medical Center Groningen (NL)
  • University College London (GB)
  • AstraZeneca (Sweden) (SE)
  • Department of Cardiovascular and metabolic diseases, Global Medicines Development, AstraZeneca, Gothenburg, Sweden
  • Department of Biometrics and Information Sciences, Bogier Clinical and IT Solutions, Raleigh, NC, USA
Corresponding author
Heerspink, Hiddo J L
Venue
Nephrology Dialysis Transplantation
Published
2018-01-23
Volume
33
Issue
11
Pages
2005-2011
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2794310633
Cited by
102
References
47
Citations by year
2026: 5 · 2025: 2 · 2024: 7 · 2023: 10 · 2022: 15 · 2021: 12 · 2020: 21 · 2019: 15 · 2018: 15
FWCI
11.02
Type
journal article
Language
en
Open access
Locations
  • Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
dapagliflozin, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, albuminuria, urinary albumin-creatinine ratio, estimated glomerular filtration rate, glycemic control, blood pressure, body weight, serum creatinine, drug safety, renal function, adverse events, dose comparison
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Adult, Aged, Albuminuria, Benzhydryl Compounds, Blood Pressure, Body Weight, Creatinine, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. https://app.cochat.ai/papers/10.1093/ndt/gfx350
The paper
Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L. (2018). Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfx350

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.